We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » GSK Looks Toward Regulatory Filing for Once-Weekly Diabetes Drug
GSK Looks Toward Regulatory Filing for Once-Weekly Diabetes Drug
April 6, 2012
GSK is readying for regulatory filings for its once-weekly injectable Type 2 diabetes treatment albiglutide after positive Phase III results in its second completed trial and primary endpoint data from five ongoing studies.